title: [Role of magnetic resonance imaging for response evaluation and predictive value of tumor biomarkers in the neoadjuvant chemotherapy for breast cancer:a multi-center prospective study].
abstract: OBJECTIVE
  To explore the value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in monitoring therapy responses and analyze the predictive value of tumor biomarkers in neoadjuvant chemotherapy for breast cancer.
  
  
  METHODS
  From August 2010 to August 2013, the patients diagnosed as primary invasive breast cancer were admitted into this multi-center study. All of them received 6 cycles of neoadjuvant chemotherapy and DCE-MRI during the procedure and underwent surgery. The associations between clinical therapy response and pathologic response as well as predictive factors were analyzed.
  
  
  RESULTS
  As for evaluating neoadjuvant treatment response, DCE-MRI had statistically significant correlations with histopathology. PR negativity, HER-2 over-expression and high Ki-67 index were statistically correlated with pathologic complete response (pCR) (P < 0.05).
  
  
  CONCLUSIONS
  DCE-MRI is a reliable method of assessing the response of neoadjuvant therapy for breast cancer. And the immunohistochemistry status of PR, HER-2 and Ki-67 were related with pCR.
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Xin
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Liu
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Zefei
authors.initials: Z
authors.lastname: Jiang
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Hongchuan
authors.initials: H
authors.lastname: Jiang
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Naishan
authors.initials: N
authors.lastname: Qin
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Li
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xuening
authors.initials: X
authors.lastname: Duan
authors.affiliation: Breast Disease Center, Peking University First Hospital, Beijing 100034, China. Email: liuyinhua@medmail.com.cn.
authors.forename: Yinhua
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000628:therapy*; D003287:Contrast Media; D006801:Humans; D008279:Magnetic Resonance Imaging; D020360:Neoadjuvant Therapy; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D003287:Contrast Media; D018719:Erb-b2 Receptor Tyrosine Kinases